News on cancer research & diagnostics, liquid biopsy, and cancer risk testing.
The updated guidelines confirm HER2 gene amplification assessed by ISH and protein overexpression assessed by IHC are primary predictors of responsiveness to HER2 therapy.
Cigna is the first national private payor to provider coverage for the Decipher tests, which provide a genomic assessment of tumor aggressiveness.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
A new company will be established to develop a service platform using blockchain technology for medical services and personalized health management.
The Belgian cancer center plans to evaluate Natera's ctDNA assay for evaluating response and detecting minimal residual disease in breast cancer patients.
